Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP reductase (FabI).
Miller, W.H., Seefeld, M.A., Newlander, K.A., Uzinskas, I.N., Burgess, W.J., Heerding, D.A., Yuan, C.C., Head, M.S., Payne, D.J., Rittenhouse, S.F., Moore, T.D., Pearson, S.C., Berry, V., DeWolf Jr., W.E., Keller, P.M., Polizzi, B.J., Qiu, X., Janson, C.A., Huffman, W.F.(2002) J Med Chem 45: 3246-3256
- PubMed: 12109908 
- DOI: 10.1021/jm020050+
- Primary Citation of Related Structures:  
1LX6, 1LXC - PubMed Abstract: 
Bacterial enoyl-ACP reductase (FabI) catalyzes the final step in each cycle of bacterial fatty acid biosynthesis and is an attractive target for the development of new antibacterial agents. Our efforts to identify potent, selective FabI inhibitors began with screening of the GlaxoSmithKline proprietary compound collection, which identified several small-molecule inhibitors of Staphylococcus aureus FabI ...